QI
NVO

Qtron Investments’s Novo Nordisk NVO Stock Holding History

Qtron Investments’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Sell
23,127
-2,879
-11% -$124K 0.15% 147
2026
Q1 		$956K Hold
26,006
– – 0.13% 194
2025
Q4 		$1.32M Sell
26,006
-1,663
-6% -$85K 0.17% 123
2025
Q3 		$1.54M Sell
27,669
-6,503
-19% -$381K 0.19% 121
2025
Q2 		$2.36M Sell
34,172
-1,593
-4% -$108K 0.3% 56
2025
Q1 		$2.48M Hold
35,765
– – 0.37% 48
2024
Q4 		$3.08M Sell
35,765
-6,750
-16% -$730K 0.43% 33
2024
Q3 		$5.06M Sell
42,515
-506
-1% -$67.5K 0.69% 19
2024
Q2 		$6.14M Hold
43,021
– – 0.89% 14
2024
Q1 		$5.52M Buy
43,021
+4,647
+12% +$553K 0.78% 16
2023
Q4 		$3.97M Sell
38,374
-470
-1% -$46.5K 0.65% 24
2023
Q3 		$3.53M Hold
38,844
– – 0.67% 27
2023
Q2 		$3.14M Sell
38,844
-1,370
-3% -$112K 0.6% 33
2023
Q1 		$3.2M Sell
40,214
-2,388
-6% -$169K 0.66% 29
2022
Q4 		$2.88M Buy
42,602
+1,602
+4% +$93.9K 0.61% 32
2022
Q3 		$2.04M Buy
41,000
+4,640
+13% +$249K 0.51% 38
2022
Q2 		$2.03M Sell
36,360
-160
-0.4% -$8.88K 0.45% 47
2022
Q1 		$2.03M Sell
36,520
-34
-0.1% -$1.75K 0.45% 49
2021
Q4 		$2.05M Sell
36,554
-4,430
-11% -$240K 0.46% 46
2021
Q3 		$1.97M Buy
40,984
+13,730
+50% +$664K 0.53% 45
2021
Q2 		$1.14M Buy
27,254
+30
+0.1% +$1.16K 0.29% 73
2021
Q1 		$918K Buy
27,224
+6,164
+29% +$220K 0.26% 97
2020
Q4 		$736K Buy
21,060
+3,610
+21% +$125K 0.2% 119
2020
Q3 		$606K Sell
17,450
-17,272
-50% -$576K 0.21% 110
2020
Q2 		$1.14M Sell
34,722
-5,062
-13% -$162K 0.45% 42
2020
Q1 		$1.2M Buy
39,784
+7,800
+24% +$232K 0.72% 23
2019
Q4 		$926K Buy
31,984
+14,408
+82% +$399K 0.53% 46
2019
Q3 		$454K Hold
17,576
– – 0.28% 123
2019
Q2 		$449K Buy
17,576
+8,750
+99% +$216K 0.28% 127
2019
Q1 		$231K Buy
+8,826
New +$217K 0.21% 172

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Qtron Investments's NVO Position: Q2 2026 in Review

Qtron Investments reduced its Novo Nordisk (NVO) stake by 11% in Q2 2026, selling an estimated $124K and leaving 23,127 shares worth $1.11M. The position accounts for 0.15% of the portfolio, ranked #147.

Qtron Investments first reported a position in NVO in Q1 2019 and has held it in 30 quarters since. The position peaked at $6.14M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Qtron Investments held 23,127 shares of Novo Nordisk worth $1.11M as of Q2 2026.
  • Qtron Investments sold 2,879 Novo Nordisk shares in Q2 2026, an estimated $124K.
  • Novo Nordisk made up 0.15% of Qtron Investments's portfolio in Q2 2026, its #147 holding.
  • Qtron Investments first reported a position in Novo Nordisk in Q1 2019 and has held it in 30 quarters since.
  • Qtron Investments's Novo Nordisk position peaked at $6.14M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Qtron Investments's 13F filing for Q2 2026, filed 13 Aug 2026.